tag pharma-branding 
pharmaphorum
SEPTEMBER 15, 2020
As pharmaceutical marketers prepare their brands for the future, there are a number of important ways they can learn from digitally-native brands. Analysing the world of digitally-native brands highlights three standout ways in which parts of their approach could be brought to the pharmaceutical world. Be more agile .
pharmaphorum
AUGUST 17, 2020
N o one industry is ever quite like another, but there are some valuable lessons for pharma marketing from examining how the financial sector uses technology, builds brands on social channels and approaches digital content. Nevertheless, the advent of COVID-19 is forcing pharma, and many other sectors, to make some radical changes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Viseven
NOVEMBER 30, 2022
Tata Consultancy Services , about the evolution of pharma marketing: The most prominent subjects that display the look and feel of pharma marketing today are the saturation of multichannel marketing strategy and the maturing state of omnichannel marketing.?. And consequently, they also expect service from their pharma ecosystem.
Viseven
JUNE 23, 2022
The faster digitalization goes worldwide, the more pharma companies find out about new tools and approaches for digital self-promotion. Pharma and the specialties of pharma’s marketing appeared to be under influence as well. Modern days marketers are as good as quickly they adapt and overcome today’s challenges.
Pharmaceutical Technology
FEBRUARY 10, 2023
This is not the first treatment to come with a high price tag. Because RSAs traditionally involve high cost/highly innovative drugs, GlobalData has reviewed the top brands according to volume of RSAs granted and Anatomical Therapeutic Chemical (ATC) code.
Pharmaceutical Technology
JULY 14, 2022
Due to the high price tags associated with these speciality medicines, innovators have naturally favoured big markets with high GDP such as the US and EU-5 (Germany, France, Spain, Italy, and the UK). Go-to-market strategies. The choice of where to launch an orphan drug is an important and difficult decision.
pharmaphorum
MAY 17, 2021
Apellis Pharma has secured FDA approval for its complement C3 inhibitor Empaveli as a treatment for paroxysmal nocturnal hemoglobinuria (PNH) – with a label that will allow it to challenge Alexion’s established therapies directly. . billion and $1.1
Expert insights. Personalized for you.
118 
Let's personalize your content